Healthcare / Drug Manufacturers - Specialty & GenericKuala Lumpur
$0.24
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $1.7M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$66M
P/E
24.0x
↑EV/EBITDA
15.0x
↑ROE
3.6%
↑Gross Margin
12.8%
↓Debt/Equity
0.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-1.4%
FCF CAGR
-32.1%
FCF margin
1.0%
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $176.0M · net income $2.8M · FCF $1.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $176.0M | $176.0M | $186.2M | $161.6M | $183.8M |
| Net Income | $2.8M | $2.8M | $3.4M | $3.6M | $5.5M |
| EBITDA | $4.7M | $4.7M | $6.2M | $7.1M | $11.5M |
| EPS | — | — | 0.01 | 0.01 | 0.02 |
| Gross Margin | 12.8% | 12.8% | 12.2% | 12.7% | 14.0% |
| Operating Margin | 2.7% | 2.7% | 3.3% | 3.2% | 5.1% |
| Net Margin | 1.6% | 1.6% | 1.9% | 2.2% | 3.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.23 | 0.23 | 0.28 | 0.17 | 0.27 |
| Current Ratio | 2.73 | 2.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.7M | $1.7M | $-2.7M | $6.1M | $5.4M |
| Returns | |||||
| ROE | 3.6% | 3.6% | 4.4% | 4.8% | 7.6% |
| Valuation | |||||
| P/E | 24.00 | 24.00 | 17.20 | 14.50 | 11.25 |
| EV/EBITDA | 15.03 | 15.03 | 10.47 | 7.66 | 5.83 |
| P/B | 0.83 | 0.83 | 0.76 | 0.70 | 0.85 |
| Growth & Yield | |||||
| Revenue Growth | -5.5% | -5.5% | 15.2% | -12.1% | — |
| EPS Growth | — | — | -4.6% | -34.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.2%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → n/d
Residual
-26.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.